← SynDRA
DOFEQUIDAR
SynDRA canonical compound SYN0002862 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | ABCB1 |
|---|
| Mechanism of action | P-glycoprotein inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MRP INHIBITOR
- P-glycoprotein inhibitor
- P glycoprotein inhibitor
Drug classes
Cross-references
Synonyms
- 0BJK6B565B
- dofequidarum
- RefChem:135562
- DTXCID10817702
- Dofequidar [INN]
- MS209
- UNII-0BJK6B565B
- C30H31N3O3
- DOFEQUIDAR [WHO-DD]
- orb1679065
- SCHEMBL2848386
- SCHEMBL29351485
- KLWUUPVJTLHYIM-UHFFFAOYSA-N
- EBC-06062
- MFCD09838435
- NCGC00378575-01
- NCGC00378575-04
- DA-72877
- HY-17013
- EN300-6487183
- BRD-A14941520-051-01-0
- Z278165154
- orb1309752
- HY-17013A
- F84996
- MS-209 (sesquifumarate)
- C34H35N3O7
- MFCD00925095
- T11071
- MS-30594
- Dofequidar (sesquifumarate)
- Dofequidar (fumarate)
- SCHEMBL2850163
- CS-2041
- DA-62988
- SCHEMBL29399301
- AKOS030526583
- 3DM793MFSE
Look up DOFEQUIDAR in the interactive SynDRA portal →